人类 DNA 疫苗市场 - 全球行业规模、份额、趋势、竞争、机会、预测，2018-2028 年，按管理途径、按应用、按最终用户、按地区、竞争

由于人类癌症和传染病的流行率不断上升，全球人类 DNA 疫苗市场预计在 2024-2028 年预测期内将出现显着增长。

根据全球癌症观察站的数据，2020 年全球报告了大约 19,292,789 例新癌症病例。 乳腺癌、肺癌、结直肠癌、前列腺癌和胃癌是 2020 年报告的最常见癌症类型。 此外，越来越多的抗生素耐药病原体预计将进一步推动人类 DNA 疫苗市场的增长。

各种疾病的患病率上升

在全球范围内，癌症是导致死亡的主要原因。 根据世界卫生组织 (WHO) 的数据，在过去五年中，全世界报告了大约 50,550,287 例癌症病例。 这包括紫外线和电离辐射等物理致癌物、石棉等化学致癌物、烟草烟雾成分、酒精、黄曲霉毒素（一种食品污染物）、砷（一种饮用水污染物）、某些病毒和细菌。如寄生虫感染和不健康的生活方式。 癌症已成为全球性的医疗保健挑战。 开发抗癌疗法的需求预计将支持全球人类 DNA 疫苗市场的增长。 同样，艾滋病毒、人乳头瘤病毒和肺结核等致命和潜在治疗疾病的流行率不断上升，预计将进一步推动全球人类 DNA 疫苗市场的增长。 截至 2021 年，全球约有 3840 万人感染艾滋病毒。

抗生素耐药病原体增加

抗生素耐药性是对全球健康、粮食安全和发展的最大威胁之一。 流行病学模型描述了抗生素消耗与耐药病原体之间的直接关係。 根据世界卫生组织 (WHO) 的数据，已在临床开发中确定了 32 种抗生素，这些抗生素旨在对抗最优先的病原体。 在引起传染病的被称为“超级细菌”的多重耐药菌中，有一些无法用抗生素等现有抗菌药物治疗。 此外，某些细菌对现有疗法产生了耐药性，因此需要开发能够解决抗生素耐药性问题的新型治疗方案。 预计这将推动全球人类 DNA 疫苗市场的增长。

DNA 疫苗研发的增长

研发 (R&D) 实践和活动的快速发展正在推动市场的增长，因为开发新的人源化疫苗以治疗各种危及生命的疾病的需求不断增长。我来了。 Clinicaltrials.gov 已在全球范围内确定了 247 项处于不同开发阶段的人类 DNA 疫苗临床试验。 这清楚地表明，世界各地正在进行大量研究和开发，以开髮用于治疗各种疾病的人类 DNA 疫苗，这有助于全球人类 DNA 疫苗市场的增长。

近期发展

ZyCoV-D 是一种基于 DNA 质粒的 COVID-19 疫苗，由印度製药公司 Cadira Healthcare 在生物技术产业研究援助委员会的支持下于 2021 年 8 月开发。 该疫苗已证明具有更高的安全性、有效性和免疫原性。 该疫苗无需注射即可注射到皮肤上，在临床试验中已被证明可提供 67% 的针对症状性 COVID-19 的保护。 ZyCoV-D 是一种采用 PharmaJet 无针系统 Tropis 的 3 剂皮内疫苗，可显着减少任何副作用并提高质量。 Zydus Cadila 已获得印度药品监管局（DCGI）对 ZyCoV-D 的紧急使用授权（EUA）批准。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第 5 章人类 DNA 疫苗的全球市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径（肌内註射、皮下注射、皮内註射、其他（静脉注射等））
  • 按应用（癌症、肺结核、HIV、其他（肝炎、流感等））
  • 按最终用户（医院/诊所、生物技术/製药公司、学术/研究机构、其他（门诊手术中心、疗养院等））
  • 按地区（北美、欧洲、亚太地区、南美、中东/非洲）
  • 按公司分类（2022 年）
• 市场地图
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按地区

第6章北美人类DNA疫苗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章欧洲人类 DNA 疫苗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按国家
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 意大利
  • 西班牙

第8章亚太地区人类DNA疫苗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚

第9章南美人类DNA疫苗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章中东和非洲人类 DNA 疫苗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按给药途径
  • 通过使用
  • 最终用户
  • 按国家
• MEA：国家分析
  • 阿联酋人类 DNA 疫苗
  • 沙特阿拉伯人类 DNA 疫苗
  • 南非人类 DNA 疫苗

第 11 章市场动态

• 司机
• 任务

第12章市场趋势与发展

第13章临床试验分析

• 正在进行的临床试验
• 已完成临床试验
• 中止的临床试验
• 管道细分，按开发阶段
• 管道细分，按状态
• 按研究应用划分的管道细分
• 按地区划分的渠道细分
• 临床试验热图

第14章竞争格局

• BOEHRINGER INGELHEIM GmbH（Merial）
• ELI-LILLY（Novartis Animal Health）
• GeneOne Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals（VGX Animal Health）
• Genexine, Inc.
• VIATRIS INC.（Rottapharm Biotech）
• Takara Holdings（Takara Bio）
• ZOETIS INC.（Fort dodge Animal Health）
• Zydus Cadila

第 15 章战略建议

Global Human DNA Vaccine Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide. Breast Cancer, Lung Cancer, Colorectum Cancer, Prostate Cancer, and Stomach Cancer were the most prevalent types of cancer cases reported in 2020. Additionally, an increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market.

The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.

Rise in Prevalence of Different Diseases

Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.

Increase in Number of Antibiotics Resistant Pathogens

Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens. Some multi and resistant bacteria called "superbugs" that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.

Growth in R&D for DNA Vaccine

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.

Recent Developments

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.

Market Segmentation

Global Human DNA Vaccine Market can be segmented based on the mode of administration, application, end user, and region. Based on the mode of administration, the market can be categorized into intramuscular, subcutaneous, intradermal, and others. Based on application, the market can be fragmented into oncology, tuberculosis, HIV, human papillomavirus, and others. Based on end users, the market can be grouped into hospitals & clinics, biotechnology & pharmaceutical companies, academic & research institutions, and others.

Company Profiles

BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort Dodge Animal Health), Zydus Lifesciences Limited are some of the key players operating in the global Human DNA Vaccine market.

Report Scope

In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Human DNA Vaccine Market, By Mode of Administration:

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Human DNA Vaccine Market, By Application:

• Oncology
• Tuberculosis
• HIV
• Human Papillomavirus
• Others

Human DNA Vaccine Market, By End User:

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Human DNA Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Human DNA Vaccine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human DNA Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others include (Intravenous, etc.)
  • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others include (Hepatitis, Influenza, etc.)
  • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others include (Ambulatory surgical centers, Nursing homes, etc.)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Application
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Human DNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human DNA Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Human DNA Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Human DNA Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human DNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Human DNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Human DNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Human DNA Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1.1. By Route of Administration
      • 7.3.4.2.1.2. By Application
      • 7.3.4.2.1.3. By End User
  • 7.3.5. Spain Human DNA Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human DNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan Human DNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. India Human DNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Human DNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Human DNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human DNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Human DNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Human DNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Human DNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. South Africa Human DNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Application
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (In Case of Listed Companies)
• 14.5. Key Personnel
  • 14.5.1. BOEHRINGER INGELHEIM GmbH (Merial)
  • 14.5.2. ELI-LILLY (Novartis Animal Health)
  • 14.5.3. GeneOne Life Science
  • 14.5.4. GEOVAX LABS, INC
  • 14.5.5. Inovio Pharmaceuticals (VGX Animal Health)
  • 14.5.6. Genexine, Inc.
  • 14.5.7. VIATRIS INC. (Rottapharm Biotech)
  • 14.5.8. Takara Holdings (Takara Bio)
  • 14.5.9. ZOETIS INC. (Fort dodge Animal Health)
  • 14.5.10. Zydus Cadila

15. Strategic Recommendations